Better Therapeutics, Inc. · OTC:BTTX

Better Therapeutics — SPAC Merger (April 2021)

36 slides from Better Therapeutics's SPAC merger presentation, Apr 7, 2021

  1. Slide 1: Pioneering a prescription digital therapeutics platform for cardiometabolic diseases

    INVESTOR PRESENTATION | MARCH 2021 Pioneering a prescription digital therapeutics platform for cardiometabolic diseases

  2. Slide 2: Disclaimer

    Disclaimer This presentation (“Presentation”) is for informational purposes only to assist interested parties in making their own evaluation with respect to the proposed business combination (the “Business Combination”) between Mountain Crest Acquisition Corp. II (“Mountain Crest”) and Better Therap

  3. Slide 3: Risk Factors

    Risk Factors The list below of risk factors has been prepared as part of the Business Combination. The risks presented below are certain of the general risks related to the business of BetterTx and the Business Combination, and such list is not exhaustive. The list below is qualified in its entirety

  4. Slide 4: Transaction Overview

    TRANSACTION OVERVIEW 4 Better Therapeutics has agreed to a proposed business combination with Mountain Crest Acquisition Corp. II Transaction Structure $57.5M SPAC; $50.0M PIPE Use of Proceeds The company intends to use the net proceeds from this transaction to advance its clinical pipeline and for

  5. Slide 5: Co-Founders David Perry and Kevin Appelbaum

    David Perry Co - Founder, Executive Chairman 5 Kevin Appelbaum Co - Founder, Chief Executive Officer CEO of Tria Beauty • Created a new category of skincare by being the first to bring FDA - regulated ( 510 k) medical lasers (class II) over - the - counter for home use • Scaled from pre clinical to

  6. Slide 6: Next Generation Therapeutics: Using Software Instead of Drugs

    6 A Digital Therapeutics Platform – delivering novel cognitive behavioral therapy targeting the root causes of cardiometabolic diseases Demonstrated Results – clinically meaningful results in multiple trials for Type 2 Diabetes and Hypertension Major Market Opportunities – $490 billion 1 spent in tr

  7. Slide 7: We are spending more and more money to get worse and worse outcomes

    0 2 7 . 5 55 82 . 5 110 1965 1 9 75 1985 1995 2005 2015 We are spending more and more money to get worse and worse outcomes THE PROBLEM DIABETES Americans Diagnosed with Diabetes (millions) US Healthcare Expenditures ($ in trillions) $4 $3 $2 $1 Americans Diagnosed with Hypertension (millions) US He

  8. Slide 8: Over $100B/year spent on drugs treating effects of three diseases

    Hypertension (high blood pressure) Type 2 Diabetes (high blood sugar) 35M people $52B Rx drug spending 70M people $30B Rx drug spending Hyperlipidemia (High cholesterol) 40M people $28B Rx drug spending We are spending over $100B/year on drugs that treat the effects of just three diseases, none of w

  9. Slide 9: Cognitive Behavioral Therapy is effective but not scalable or affordable

    9 There is ample evidence that focused Cognitive Behavioral Therapy (CBT) is effective at treating cardiometabolic diseases. However, traditional methods of CBT (1 on 1 or group therap y) are neither scalable nor affordable for the broader population. THE PROBLEM “The results of this study show that

  10. Slide 10: Better Therapeutics founding hypothesis: software to change patient behavior

    Better Therapeutics was founded on the hypothesis that we could create software that would change patient behavior and treat underlying causes of cardiometabolic diseases; 10 and deliver it in a scalable and affordable mobile application

  11. Slide 11: Regulatory Pathway: de novo classification request

    Our first submission will be a de novo classification request 11 Subsequent submissions may be 510(k)s Pear Therapeutics, Akili Interactive, Apple, Lilly, and Verily have received clearances via this approach in recent months In 2017, the FDA established a pathway for the approval of software REGULA

  12. Slide 12: Patient and provider demand for alternatives addressing underlying causes

    Both patients and healthcare providers are highly interested in treatment alternatives that address the underlying causes of disease 6% 19% 31% 38% 6% 1 2 3 4 5 6 7 P atient A v e r age 5 . 8 / 7 Patient Qualitative Research Results (n=20) 69% r a t e it a 6 or 7 5 2% 28% 14% 7% 1 2 3 4 5 6 7 Provid

  13. Slide 13: Payer Coverage: research supports pricing assumption

    PAYER COVERAGE Payer research supports our pricing assumption • Blinded interviews conducted with 8 key decision - makers across Commercial, Medicare and Medicaid payers • Payers responded favorably to BT - 001 target product profile with a willingness to reimburse within the range of other branded

  14. Slide 14: Now is a unique time to build a valuable company

    Now is a unique time to build a very valuable company; one that is based on Prescription Digital Therapeutics We can’t continue to pay more money for worse outcomes CBT is well established to treat the underlying causes of these diseases Better Therapeutics has created a software platform that has d

  15. Slide 15: Mechanism of Action

    MECHANISM OF ACTION We have created a software platform that has demonstrated clinically meaningful results in multiple trials A R TIFICIA L INTELLIGENCE NEUROSCIENCE LIFE S T YL E MEDICINE Behavioral Therapy Changes thoughts and beliefs so that difficult behavior changes are possible. Builds the ac

  16. Slide 16: Clinical Data

    Better Clinical Data

  17. Slide 17: Results versus oral diabetes and antihypertensive medications

    1. The Effect of Oral Anti - diabetic Agents on A1C Levels, Diabetes Care, Volume 33(8); 2010 Aug. 2. Global Sales metrics from FiercePharma, Zion Market Research. 3. 74% of studies between 12 - 24 weeks. 4. Treatment efficacy of anti - hypertensive drugs in mono therapy or combination. Medicine (20

  18. Slide 18: Change in fasting blood glucose and A1c

    1 18 The FDA approvable endpoint for drugs is a reduction in A1c of - 0.4% compared to control after 12 weeks of treatment 2 Type 2 diabetes is defined as an A1c of 6.5% or higher Change in Fasting Blood Glucose (n = 80, enrolled with baseline A1c 7.0 to 11.0%) 2 All Study W eek Mean (mg/dL) Es t .

  19. Slide 19: Clinical Development Plan

    Clinical Development Plan 19

  20. Slide 20: Pivotal Trial Summary - BT-001

    PIVOTAL TRIAL SUMMARY - BT - 001 A single pivotal trial to seek FDA authorization for the treatment of type 2 diabetes is underway and we expect data in Q4 2021 Sample Size : 648 participants with type 2 diabetes located in 5 geographically distinct US regions Po w er : 90% p o w er t o d e t ect 0

  21. Slide 21: Clinical Development

    CLINICAL DEVELOPMENT Q 1 2021 Q2 2021 Jan Feb Mar Q3 2021 Apr May Jun Q4 2021 Jul Aug Sep Q 1 202 2 Oct Nov Dec Q2 2022 Q3 2022 Type 2 Diabetes (T2DM)* T2DM w/ Hypertension Hypertension Tx Resistant Hypertension Hyperlipidemia Familial Hyperlipidemia Hypertriglyceridemia NAFLD N A SH Chronic Kidney

  22. Slide 22: Commercial Launch Plans for BT-001

    Commercial Launch Plans for BT - 001 22

  23. Slide 23: Current treatment paradigm: symptoms worsen and costs increase

    In the current treatment paradigm, disease symptoms worsen and healthcare costs increase for the remainder of life. Advanced Comorbidities Diagnosis Additional Non - Insulin Treatments Progression of Disease Pre - Diabetes / At - Risk Stage +1.8x drug cost / patient / y ear +3.2x drug cost / patient

  24. Slide 24: A new paradigm by treating underlying causes of disease

    By treating the underlying causes of disease, we make a new paradigm possible; one in which disease progression stops and many patients are cured. Insulin Treatment Diagnosis Non - Insulin Treatment Additional Non - Insulin Treatments Progression of Disease Pre - Diabetes / At - Risk Stage Reduce th

  25. Slide 25: Immediate Total Addressable Market

    12 M Patients with uncontrolled diabetes and A1c 7 - 11% 73 % Covered by Commercial Payers or Medicare Part D $ 4 , 500 Annual diabetes drug costs per patient IMMEDIATE TOTAL ADDRESSABLE MARKET (TAM) In diabetes alone, there is over $40B of addressable drug spending on insured patients with uncontro

  26. Slide 26: Diabetes drug spending outlook to 2030

    $0 $30 $60 $90 $120 2030 w/BT - 001 authorized $15B $40B $105B Diabetes drug spending is expected to grow by 2.5x over the next 10 years, but our approach could begin to reduce the cost of treating diabetes and almost every other metabolic disease. $93B 2010 Y e s t e r d a y 26 2020 Today 2030 Tomo

  27. Slide 27: New Business Model: FDA authorization and payer reimbursement like a drug

    Physician examines patient By choosing to seek FDA authorization for our products, we seek to fit seamlessly within the existing healthcare system to enable adoption and scale, while only changing the form of therapy Physician diagnoses patient Physician prescribes therapy Payer reimburses like a dr

  28. Slide 28: Provider Engagement

    P atients 0 5 , 75 0 , 000 11,500,000 1 7 ,25 0 , 000 23,000,000 0 10 0 , 000 200,000 Primary Care Providers 30 0 , 000 40 0 , 000 38 8 , 7 17 28 2 2 4 , 364 162,082 121,206 9 0 , 558 6 6 , 2 49 4 6 , 468 2 3 , 592 1 6 , 998 6 , 636 PROVIDER ENGAGEMENT 86% of type 2 diabetes patient care (pre insuli

  29. Slide 29: Go-to-Market: commercial team composition

    G O - T O - MARK E T We plan to build a commercial capability to launch BT - 001 and scale an emerging portfolio of digital therapeutics in primary care . Commercial Team Composition R ole F ocus Sizing 6 Mos. Post Clearance Annuali z ed C o st Provider Engagement Health System support, high priorit

  30. Slide 30: Reimbursement: BT-001 versus branded drugs

    Clinical Impact (A1c Reduction) T rulicity (GL P - 1 R A Inj.) Rybelsus (GL P - 1 R A O r al) Jardiance (SGLT2) Janum e t (DPP4) 1 . 0 % 0.8% 0 . 9 % 1.2% 1 . 7 % Type 2 Diabetes Branded Drug 3 Year Costs T rulicity (GL P - 1 R A Inj.) Rybelsus (GL P - 1 R A O r al) Jardiance (SGLT2) Janum e t (DPP4

  31. Slide 31: Financial Forecast

    Better Financial Forecast at

  32. Slide 32: Revenues, gross profit and EBIT forecast

    R e v enu e s $0 $100 $200 $300 $400 2021 20 2 2 2023 (Launch Year) 20 2 4 2025 $390 $88 $7 G r o s s P r o fit - $100 $0 $100 $200 $300 $400 2021 20 2 2 2023 20 2 4 2025 $310 $63 $1 - $2 $0 EBIT - $140 32 - $105 - $7 0 - $35 $0 $35 2021 20 2 2 2023 20 2 4 2025 $16 - $132 - $117 - $43 - $23 Better T

  33. Slide 33: Platform Net Revenue

    Platform Net Revenue $600 $1,200 $1 , 800 $2 , 400 $ 3 , 000 2021 20 2 2 2023 20 2 4 2025 2026 20 2 7 T2D HTN HLD NAFLD N A SH CKD 33 And Better Therapeutics’ platform creates the opportunity to build a best in class Prescription Digital Therapeutics company Projections assume 6% peak market share f

  34. Slide 34: Financial Highlights

    FINANCIAL HIGHLIGHTS $40.8M Gross Proceeds Raised Sin c e Compa n y F ormation in 2015 $3.9M as of 3/14/21 Cash & Cash Equivalents $.6M as of 3/14/21 Debt (PPP loan which is expected to be forgiven) 34 Seed: $2 . 0M Q4 2015 Seri e s A: $ 2 2.2M Q4 2017 Simple A g r eements f or F u tu r e E quity: $

  35. Slide 35: Pro Forma Shares & Ownership; Transaction Detail

    Pro Forma Shares & Ownership at Transaction Closing (in millions) PF Shares Ownership SPAC Sponsor Shares SPAC Sponsor Shares (Mountain Crest) SPAC Sponsor Shares (Better Tx) Public Shareholders Better Tx Equity Roll - Over PIPE Private Placement Shares Underwriter’s Shares Shares from Rights 1.4 1.

  36. Slide 36: Financing Plan and value creation milestones

    Q1 2021 Cumulative Cash: $4M Q2 2021 $10M Q3 2021 $16M Q4 2021 $23M Q2 20 2 2 $42M Q1 20 2 2 $31M Q3 20 2 2 $53M Q4 20 2 2 $65M FINANCING PLAN We expect multiple value creation milestones over the next two years 12 mon. A C O da t a S t ar t o f Pivotal [T 2 D] In t erim Da t a [T2D] Se c onda r y E

Better Therapeutics — SPAC Merger (April 2021) on 6ix